Calliditas Therapeutics AB Overview
Pro stress-test →Calliditas Therapeutics is a biopharma company headquartered in Stockholm, Sweden, focused on identifying, developing, and commercializing novel treatments in orphan indications with significant unmet medical needs. The company specializes in rare renal and hepatic diseases, with TARPEYO (budesonide) as its commercial-stage lead product generating significant revenues.
Strategic Profile
Pro stress-test →Calliditas Therapeutics AB (Nasdaq: CALT) is majority-owned by Asahi Kasei following its acquisition of over 90% of outstanding shares (September 2024). The company demonstrates strong commercial traction, with preliminary Net TARPEYO revenues of $100–102m for 2023, representing over 170% year-over-year growth compared to 2022.
Competitive Landscape
Pro stress-test →Calliditas operates in the rare disease immunosuppressant space, competing indirectly with standard corticosteroid therapies and other emerging targeted treatments for autoimmune renal diseases. Primary differentiation derives from proprietary formulation (TARPEYO/Nefecon) that delivers budesonide directly to renal tissue, improving safety and efficacy profiles compared to systemic corticosteroids.
Industry Context
Calliditas Therapeutics AB operates in Orphan indication biopharmaceuticals.
Key facts
Founded: 2004 · Headquarters: Stockholm, Sweden · Employees: N/A · Revenue: $100-102M · Market cap: $1.1B